Clinical context
In glaucoma, intraocular pressure reduction is important but remains a surrogate outcome. Clinical value also depends on preservation of the visual field and optic nerve, safety, the need for additional medication or surgery, and treatment adherence. Target pressure is individualized, so the same numerical change can carry different meaning at different disease stages and rates of progression.
What was studied
This multicenter open-label randomized noninferiority trial compared phacogoniotomy with phacotrabeculectomy in cataract and advanced primary angle-closure glaucoma. The groups included 65 and 59 eyes. The primary endpoint was intraocular-pressure reduction at three years, with a prespecified noninferiority margin of 4 mmHg. Secondary outcomes included complete and qualified success, medication, complications, corrected vision, visual field and endothelial-cell density.
How the evidence was produced
Randomization reduces the influence of known and unknown confounders and makes comparisons between interventions more reliable. Readers should still examine sequence generation, allocation concealment, masking of outcome assessors, the prespecified primary endpoint, losses to follow-up and intention-to-treat analysis. These details determine how confidently an observed difference can be attributed to the intervention.
How to interpret the result
At three years, phacogoniotomy achieved pressure reduction within the prespecified noninferiority margin. This matters in advanced angle-closure glaucoma, where low pressure is needed but filtration-surgery complications matter. Noninferiority does not prove identical outcomes: complete success numerically favored trabeculectomy, while the confidence interval and margin define uncertainty. Decisions should consider synechiae, stage, target pressure and later surgery.
The result should be understood as an estimate for the population studied, not a promise of an individual outcome. Statistical and clinical significance, absolute and relative effects, and prespecified and exploratory analyses should be distinguished. When several endpoints or subgroups are reported, the prespecified primary endpoint for which the study was designed usually provides the most reliable inference.
Clinical applicability
The findings can inform discussions about treatment sequence and burden. Before changing management, compare the study population with the patient in front of you, including glaucoma stage, baseline pressure, previous treatment, angle anatomy and rate of field loss. A pressure measurement does not replace structural and functional follow-up.
Limitations
The trial was open-label. Three-year attrition differed between groups, 7.7% versus 16.9%, which can affect a noninferiority analysis. The 4-mmHg margin is clinically consequential and should be considered with intention-to-treat and per-protocol analyses. Both groups began with very high pressure, limiting extension to controlled disease. Check withdrawal reasons, sensitivity analyses, success and rescue-surgery criteria, early complications from the original trial, field severity, postoperative interventions and the goniotomy protocol.
Beyond the limitations acknowledged by the authors, confidence is affected by sample size, follow-up duration, missing data, choice of comparator and relevance of the outcomes to routine care. Uncommon complications may remain undetected even in a well-conducted study. External validity is reduced when participants, equipment or investigator expertise differ substantially from everyday settings.
What to verify in the source
In the full paper, verify the protocol, eligibility criteria, baseline group characteristics, primary endpoint definition, confidence intervals, adverse events and losses to follow-up. Funding, conflicts of interest, trial registration and consistency between the published analysis and the original plan deserve separate attention. The DOI or source link below provides access to the primary publication for this check.